Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046122 | 0.93 | CACNA1B (0.43) | PDK2CACNA1BCACNA1HMAOBLSS | |
| SCHEMBL4043584 | 0.89 | PDK2 (0.41) | PDK2CACNA1BCACNA1HMAOBLSS | |
| SCHEMBL4044268 | 0.85 | CACNA1B (0.45) | PDK2CACNA1BCACNA1HMAOBLSS | |
| SCHEMBL4046658 | 0.83 | CACNA1B (0.44) | PDK2CACNA1BCACNA1HMAOBLSS | |
| SCHEMBL4043269 | 0.83 | KDM4E (0.44) | PDK2CACNA1BCACNA1HMAOBMEN1 | |
| SCHEMBL4049133 | 0.83 | CACNA1B (0.44) | PDK2CACNA1BCACNA1HMAOBMEN1 | |
| SCHEMBL4044513 | 0.82 | SLC6A4 (0.39) | PDK2MAOBMEN1KMT2AMAOA | |
| SCHEMBL4044255 | 0.82 | PDK2 (0.43) | PDK2CACNA1BCACNA1HMAOBLSS | |
| SCHEMBL4044883 | 0.82 | CACNA1B (0.43) | PDK2CACNA1BCACNA1HMAOBMEN1 | |
| SCHEMBL6341927 | 0.82 | MAOB (0.43) | PDK2CACNA1BCACNA1HMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603921-B1 | THIADIBENZOAZULENE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-17 | — | — | EP | claimed |
| US-20060069149-A1 | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-03-30 | — | — | US | claimed |
| EP-1603921-A1 | THIADIBENZOAZULENE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-12-14 | — | — | EP | claimed |
| WO-2004078763-A1 | THIADIBENZOAZULENE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2004-09-16 | — | — | WO | claimed |
| EP-1603921-B1 | THIADIBENZOAZULENE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-17 | — | — | EP | disclosed |
| US-20060069149-A1 | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069149-A1 | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | IL1B, IL1A, TNF | PDK2 905/4885CACNA1B 2460/4885CACNA1H 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.